UBE3A ELISA Kit (Human)

7732-18-5

Ubiquitin protein ligase E3A

ANCR; AS; CTCL tumor antigen se37-2; E6-AP; E6AP ubiquitin-protein ligase; EPVE6AP; HECT-type ubiquitin transferase E3A; HPVE6A; human papilloma virus E6-associated protein; human papillomavirus E6-associated protein; oncogenic protein-associated protein E6-AP; renal carcinoma antigen NY-REN-54; ubiquitin-protein ligase E3A.

7337

Homo sapiens|Human

E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and transfers it to its substrates (PubMed:10373495, PubMed:16772533, PubMed:19204938, PubMed:19233847, PubMed:19325566, PubMed:19591933, PubMed:22645313, PubMed:24273172, PubMed:24728990) . Several substrates have been identified including the ARNTL/BMAL1, ARC, RAD23A and RAD23B, MCM7 (which is involved in DNA replication), annexin A1, the PML tumor suppressor, and the cell cycle regulator CDKN1B (PubMed:10373495, PubMed:19204938, PubMed:19325566, PubMed:19591933, PubMed:22645313, PubMed:24728990) . Additionally, may function as a cellular quality control ubiquitin ligase by helping the degradation of the cytoplasmic misfolded proteins (PubMed:19233847) . Finally, UBE3A also promotes its own degradation in vivo. Plays an important role in the regulation of the circadian clock: involved in the ubiquitination of the core clock component ARNTL/BMAL1, leading to its proteasomal degradation (PubMed:24728990) . Acts as transcriptional coactivator of progesterone receptor PGR upon progesterone hormone activation (PubMed:16772533) . Acts as a regulator of synaptic development by mediating ubiquitination and degradation of ARC (By similarity) . Synergizes with WBP2 in enhancing PGR activity (PubMed:16772533) .

ELISA Kit

Enzyme-linked immunosorbent assay

The microtiter plate provided in this kit has been pre-coated with an antibody specific to the index. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody preparation specific to the index. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain the index, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm +- 10nm. The concentration of the index in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Reconstitution & Storage Instructions Reconstitution & Storage Instructions Western Blotting/Immunoblotting (WB/IB) Protocol Western Blotting/Immunoblotting (WB/IB) Protocol Immunohistochemistry (IHC) Protocol Immunohistochemistry (IHC) Protocol Immunocytochemistry (ICC) Protocol Immunocytochemistry (ICC) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Enzyme-Linked ImmunoSorbent Assay (ELISA) Protocol Blocking Peptide Competition Protocol (BPCP) Blocking Peptide Competition Protocol (BPCP) Immunoprecipitation (IP) Protocol Immunoprecipitation (IP) Protocol Antibody Array (AA) Protocol Antibody Array (AA) Protocol

Serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

0.312-20ng/mL

Matrices listed below were spiked with certain level of recombinant the index and the recovery rates were calculated by comparing the measured value to the expected amount of the index in samples. _x005F Matrix Recovery range (%) Average (%) _x005F _x005F serum (n=5) 81-93 86 _x005F EDTA plasma (n=5) 80-97 88 _x005F heparin plasma (n=5) 90-101 95 _x005F _x005F Matrix Recovery range (%) Average (%) Matrix Recovery range (%) Average (%) Matrix Recovery range (%) Average (%) _x005F serum (n=5) 81-93 86 _x005F EDTA plasma (n=5) 80-97 88 _x005F heparin plasma (n=5) 90-101 95 _x005F serum (n=5) 81-93 86 serum (n=5) 81-93 86 EDTA plasma (n=5) 80-97 88 EDTA plasma (n=5) 80-97 88 heparin plasma (n=5) 90-101 95 heparin plasma (n=5) 90-101 95

0.102ng/mL

UBE3A

Ubiquitin-protein ligase E3A